Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

NCT03688230 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Co-development decision

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: abituzumab
COMBINATION_PRODUCT: Placebo + Cetuximab + FOLFIRI

Sponsor

SFJ Pharmaceuticals X, LTD.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]